|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Global characterization of proteome and lysine methylome features in EZH2 wild-type and mutant lymphoma cell lines.
|
31846764 |
2020 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Overexpression and gain-of-function mutations in EZH2 are regarded as oncogenic drivers in lymphoma and other malignancies due to the silencing of tumor suppressors and differentiation genes.
|
31419226 |
2019 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Enhancer of zeste homolog 2 (EZH2) and Bcl-2 gene rearrangement or protein upregulation played pivotal roles in the carcinogenesis of various malignancies including lymphomas.
|
31205561 |
2019 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Enhancer of zeste homolog 2 (EZH2), an H3K27-specific histone methyltransferase, has been shown to be frequently overexpressed in various human cancers including lymphoma.
|
30218753 |
2019 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Our findings support the clinical translation of the combination of EZH2 and HDAC inhibition in EZH2 dysregulated lymphomas.
|
30979734 |
2019 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.
|
31747604 |
2019 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Furthermore, the overexpression of EZH2, in association with coexpression of tumorigenic signaling molecules, suggests an oncogenic role for this molecule in the development of Hodgkin lymphomas and related lymphomas.
|
30371509 |
2019 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
2019; published online January 28, https://doi.org/10.1038/s41588-018-0338-y) examined the effects of mutant EZH2 on the 3D architecture of the lymphoma genome, highlighting the potential relevance of chromatin folding dynamics.
|
30885427 |
2019 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
In this review, we present the rationale, key pre-clinical and early clinical findings of small molecule EZH2 inhibitors for use in lymphoma as well as future challenges and potential opportunities for combination therapies.
|
29473431 |
2018 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Here, we critically review the emerging role of EZH2 in malignancies, the development of small molecule inhibitors of EZH2, and their application in lymphoma.
|
30112706 |
2018 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Direct binding of MALAT1 to the PRC2 components (EZH2 and SUZ12) was observed in a T cell lymphoma cell line; however, no direct binding of MALAT1 with H3K27me3 and BMI1 (a PRC1 component) was observed.In T and NK cell lymphomas, MALAT1 was related to poor prognosis.
|
28412742 |
2017 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
The antitumor efficacy of pharmacological EZH2 inhibition depends on SESTRIN1, indicating that mTORC1 control is a critical function of EZH2 in lymphoma.
|
28659443 |
2017 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma.
|
28811957 |
2017 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
We have previously shown that EZH2 inhibitors display an antiproliferative effect in multiple preclinical models of NHL, and that models bearing gain-of-function mutations in <i>EZH2</i> were consistently more sensitive to EZH2 inhibition than lymphomas with wild-type (WT) <i>EZH2</i> Here, we demonstrate that cell lines bearing <i>EZH2</i> mutations show a cytotoxic response, while cell lines with WT-<i>EZH2</i> show a cytostatic response and only tumor growth inhibition without regression in a xenograft model.
|
28835384 |
2017 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The current EZH2 inhibitors strongly suppress the enhanced enzymatic function of mutant EZH2 in some lymphomas.
|
28320739 |
2017 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
These results suggest that Ezh2(Y641F) induces lymphoma and melanoma through a vast reorganization of chromatin structure, inducing both repression and activation of polycomb-regulated loci.
|
27135738 |
2016 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
These results demonstrated that ZLD10A, as a novel EZH2 inhibitor, could be a potential promising agent for the treatment of EZH2 mutant lymphoma.
|
27261606 |
2016 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Small-molecule inhibitors against EZH2 demonstrated anti-tumor activity in EZH2-mutated lymphomas and entered clinical trials.
|
25893294 |
2016 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Herein we show that the actions of EZH2 in driving GC formation and lymphoma precursor lesions require site-specific binding by the BCL6 transcriptional repressor and the presence of a non-canonical PRC1-BCOR-CBX8 complex.
|
27505670 |
2016 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Several inhibitors of the PRC2 activity have shown efficacy in EZH2-mutated lymphomas and are currently in clinical development, although the molecular basis of inhibitor recognition remains unknown.
|
27122193 |
2016 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Importantly, the EZH2(Y641) mutants recurrently implicated in lymphoma pathogenesis are unable to bind β-TrCP.
|
24469040 |
2015 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Insights into their biological mechanisms led to the development of therapies designed to target mutant IDH1 and IDH2, DOT1L in MLL-rearranged leukemias and EZH2 in several cancer types including lymphomas.
|
25942537 |
2015 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
The reduction of CSC self-renewal via EZH2 inhibition offers a potentially attractive therapeutic approach to counter the aberrant activation found in lymphoma and leukemia.
|
24097338 |
2014 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We observed a dramatic acceleration of lymphoma development in this combination model of Myc and EZH2(Y641F).
|
24802772 |
2014 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
We discovered that YC-1 induces apoptosis and inhibits tumour growth of breast cancer cells via down-regulation of EZH2 by activating c-Cbl and ERK.
|
24697523 |
2014 |